Currently Viewing:
Newsroom
Currently Reading
Comparing Tbo-Filgrastim With Filgrastim During Neutrophil Engraftment
January 30, 2016 – AJMC Staff
Maternal Obesity, Diabetes Linked to Autism in Children
January 29, 2016 – Laura Joszt
5 Things to Know About Clinical Pathways
January 29, 2016 – Surabhi Dangi-Garimella, PhD
What We're Reading: Merck's New HCV Drug Increases Competition
January 29, 2016 – AJMC Staff
Evolving National Picture of ACA Marketplaces
January 28, 2016 – Jackie Syrop
FDA Advocates for Diversity in Clinical Trials
January 28, 2016 – Surabhi Dangi-Garimella, PhD
What We're Reading: Can a State Sue Gilead Over the High Price of Its HCV Drugs?
January 28, 2016 – AJMC Staff
Nivolumab Improved OS in SCCHN; CheckMate-141 Stopped Early
January 28, 2016 – Surabhi Dangi-Garimella, PhD
Smoking Can Reduce Survival of Breast Cancer Patients
January 27, 2016 – Surabhi Dangi-Garimella, PhD

Comparing Tbo-Filgrastim With Filgrastim During Neutrophil Engraftment

AJMC Staff
A study comparing the efficacy of tbo-filgrastim with filgrastim when used to mobilize peripheral blood stem cells or to accelerate engraftment after autologous stem cell transplantation found no clinically meaningful differences, plus tbo-filgrastim saved money.
A study comparing the efficacy of tbo-filgrastim with filgrastim when used to mobilize peripheral blood stem cells or to accelerate engraftment after autologous stem cell transplantation found that there were no clinically meaningful differences.

The paper, by researchers from the Texas Transplant Institute, was published in Biology of Blood and Marrow Transplantation.

The researchers studied patients diagnosed with lymphoma or plasma cell disorders who were undergoing granulocyte colon-stimulating factor mobilization. The primary outcome was total collected CD34(+) cells/kg.

Secondary engraftment endpoints of the study were time to neutrophil and events of febrile neutropenia. There were no statistically significant differences in these endpoints.

A total of 185 patients were included in the analysis, and the researchers found that patients receiving filgrastim collected a median of 5.56 × 10(6) CD34(+) cells/kg, compared with a median of 5.85 × 10(6) CD34(+) cells/kg in the tbo-filgrastim group.

Not only were there no statistically meaningful differences in the endpoints, such as events of febrile neutropenia and length of stay, but tbo-filgrastim was associated with savings of $1406 per patient based on the average wholesale price of the treatment.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up